Denys-Drash syndrome is a condition that affects the kidneys and genitalia.
Mutations in the WT1 gene cause Denys-Drash syndrome. The WT1 gene provides instructions for making a protein that regulates the activity of other genes by attaching (binding) to specific regions of DNA. On the basis of this action, the WT1 protein is called a transcription factor. The WT1 protein plays a role in the development of the kidneys and gonads (ovaries in females and testes in males) before birth.
The prevalence of Denys-Drash syndrome is unknown; at least 150 affected individuals have been reported in the scientific literature.
This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.
Sorahia Domenice practices in Sao Paulo, Brazil. Domenice is rated as an Elite expert by MediFind in the treatment of Denys-Drash Syndrome (DDS). They are also highly rated in 18 other conditions, according to our data. Their top areas of expertise are Intersex, Androgen Insensitivity Syndrome, Turner Syndrome, Hormone Replacement Therapy (HRT), and Orchiectomy.
Yonghui Yang practices in Fuzhou, China. Yang is rated as an Elite expert by MediFind in the treatment of Denys-Drash Syndrome (DDS). They are also highly rated in 5 other conditions, according to our data. Their top areas of expertise are Frasier Syndrome, Denys-Drash Syndrome (DDS), WT1-Related Wilms Tumor Syndromes, and Nephrotic Syndrome.
Mara Guaragna practices in Campinas, Brazil. Guaragna is rated as an Elite expert by MediFind in the treatment of Denys-Drash Syndrome (DDS). She is also highly rated in 8 other conditions, according to our data. Her top areas of expertise are Denys-Drash Syndrome (DDS), Frasier Syndrome, WT1-Related Wilms Tumor Syndromes, Intersex, and Kidney Transplant.
Summary: This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), lymphomas, or histiocytic disorders that have activating RET gene alterations. Selpercatinib may block the growth of cancer cells that have specific geneti...
Summary: This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.
Published Date: March 01, 2013Published By: National Institutes of Health